RxDoctor Payments Data

Kenneth Woods, DO

Infectious Disease · Steubenville, OHNPI 1457514937

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Insmed, Inc. accounts for 74.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $7,072 and has fallen 97.5% since, to $180 in 2025.

$8,671in general payments, 2019–2025

Across 123 payments — averaging $70.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$6K
  • Melinta Therapeutics, LLC$1K
  • Merck$282
  • Gilead$202
  • AbbVie$201
  • Viiv Healthcare Company$187
  • plus $170 from 5 others

What the payments were for

  • Consulting fees$4,55052%
  • Speaking & faculty fees$5256%
  • Travel & lodging$1,18514%
  • Food & beverage$2,26126%
  • Education$1502%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,671 in reported general payments places this provider in the 85th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$111,864
Medicare patients
262
Services billed
1,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala119$483,245
TriumeqAbacavir/Dolutegravir/Lamivudi41$158,625
DescovyEmtricitabine/Tenofov Alafenam29$61,303
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$50,339
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$36,558
DovatoDolutegravir Sodium/Lamivudine12$35,147
Vancomycin Hcl27$6,154
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam18$4,516
Penicillin G Potassium11$3,492
Cefazolin Sodium21$2,335
Cefadroxil37$539
Cephalexin39$373
Fluconazole11$320
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$247
Doxycycline Hyclate17$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$202$594,887161 claims
Viiv Healthcare CompanyTriumeq, Dovato$187$193,77253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Steubenville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →